Who Generates Higher Gross Profit? Eli Lilly and Company or Alkermes plc

A Tale of Two Companies: Eli Lilly vs. Alkermes

In the competitive world of pharmaceuticals, gross profit is a key indicator of a company's financial health and market position. Over the past decade, Eli Lilly and Company has consistently outperformed Alkermes plc in generating gross profit. From 2014 to 2023, Eli Lilly's gross profit surged by approximately 84%, reaching a peak in 2023. In contrast, Alkermes saw a more modest increase of around 726% over the same period, highlighting its growth potential despite a smaller base.

The Decade in Review

Eli Lilly's dominance is evident, with its gross profit in 2023 being nearly 20 times that of Alkermes. This disparity underscores the scale and market reach of Eli Lilly compared to its smaller counterpart. As the pharmaceutical landscape evolves, these figures provide a snapshot of the strategic positioning and financial prowess of these two industry players.